HomeCompareMLHR vs PFE

MLHR vs PFE: Dividend Comparison 2026

MLHR yields 28.99% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MLHR wins by $24.5K in total portfolio value
10 years
MLHR
MLHR
● Live price
28.99%
Share price
$38.66
Annual div
$11.21
5Y div CAGR
-7.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$74.0K
Annual income
$4,780.60
Full MLHR calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — MLHR vs PFE

📍 MLHR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMLHRPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MLHR + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MLHR pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MLHR
Annual income on $10K today (after 15% tax)
$2,463.80/yr
After 10yr DRIP, annual income (after tax)
$4,063.51/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $18,256.39/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MLHR + PFE for your $10,000?

MLHR: 50%PFE: 50%
100% PFE50/50100% MLHR
Portfolio after 10yr
$61.8K
Annual income
$15,519.66/yr
Blended yield
25.12%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

MLHR
Analyst Ratings
3
Buy
4
Hold
Consensus: Hold
Altman Z
2.5
Piotroski
6/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MLHR buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMLHRPFE
Forward yield28.99%6.13%
Annual dividend / share$11.21$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-7.3%13.2%
Portfolio after 10y$74.0K$49.6K
Annual income after 10y$4,780.60$26,258.71
Total dividends collected$40.7K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldHold

Year-by-year: MLHR vs PFE ($10,000, DRIP)

YearMLHR PortfolioMLHR Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$13,387$2,686.99$9,153$693.39+$4.2KMLHR
2$17,440$3,116.35$8,593$849.25+$8.8KMLHR
3$22,179$3,517.35$8,336$1,066.78+$13.8KMLHR
4$27,606$3,875.15$8,437$1,384.80+$19.2KMLHR
5$33,718$4,178.86$9,013$1,875.40+$24.7KMLHR
6$40,500$4,421.83$10,306$2,680.72+$30.2KMLHR
7$47,936$4,601.44$12,820$4,101.38+$35.1KMLHR
8$56,010$4,718.46$17,673$6,826.70+$38.3KMLHR
9$64,707$4,776.39$27,543$12,591.86+$37.2KMLHR
10$74,017$4,780.60$49,560$26,258.71+$24.5KMLHR

MLHR vs PFE: Complete Analysis 2026

MLHRStock

Herman Miller, Inc. engages in the research, design, manufacture, and distribution of office furniture systems, seating products, other freestanding furniture elements, textiles, home furnishings, and related services worldwide. The company offers seating products under the Embody, Aeron, Mirra2, Setu, Sayl, Verus, Cosm, Lino, Verus, Celle, Equa, Taper, and Ergon names; and modular systems under the Canvas Office Landscape, Locale, Public Office Landscape, Layout Studio, Action Office, Ethospace, Arras, Prospect, Overlay, and Resolve names. It also provides storage products under the Meridian and Tu names; wood case goods under the Geiger name; freestanding furniture products under the Abak, Intent, Sense, and Envelop names; healthcare products under the Palisade, Compass, Nala, Ava, and Nemschoff names; Thrive portfolio of ergonomic solutions, ergonomic, and technology support products under the Colebrook Bosson Saunders name; and textiles under the Maharam name, as well as Live Platform system of cloud-connected furnishings, applications, and dashboards. In addition, the company offers products for residential settings under the Eames, Eames Soft Pad, HAY, Nelson, Bubble Lamps, Airia, Ardea, Bumper, Burdick Group, Everywhere, Claw, Caper, Distil, Envelope, Formwork, Full Round, H Frame, I Beam, Landmark, Logic Mini, Logic Power Access Solutions, Renew, Rolled Arm, Scissor, Sled, Soft Pad, Swoop, Tone, Twist, Ward Bennett, and Wireframe names. Its products are used in offices and related conference, lobby, and lounge areas; transportation terminals; hospitals, clinics, and other healthcare facilities; industrial and educational settings; and residential and other environments. The company markets its products through its sales staff, own dealer network, independent dealers and retailers, and independent contract office furniture dealers, as well as through e-commerce Website. Herman Miller, Inc. was founded in 1905 and is headquartered in Zeeland, Michigan.

Full MLHR Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this MLHR vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MLHR vs SCHDMLHR vs JEPIMLHR vs OMLHR vs KOMLHR vs MAINMLHR vs JNJMLHR vs MRKMLHR vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.